Dated: November 4, 2010.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2010–28597 Filed 11–12–10; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, Office of Infectious Diseases, (BSC, OID)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

Time and Date: 8:30 a.m.–5 p.m., December 6, 2010.

Place: CDC, Global Communications Center, 1600 Clifton Road, NE., Building 19, Auditorium B1–B2, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: The BSC, OID, provides advice and guidance to the Secretary, Department of Health and Human Services; the Director, CDC; the Director, OID; and the Directors of the National Center for Immunization and Respiratory Diseases, the National Center for Emerging and Zoonotic Infectious Diseases, and the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, in the following areas: strategies, goals, and priorities for programs; research within the national centers; and overall strategic direction and focus of OID and the national centers.

Matters to be Discussed: The agenda will include OID and center updates, followed by a focused discussion to solicit recommendations from the board on a strategic document designed to increase the public health impact of CDC's infectious disease prevention and control efforts.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Robin Moseley, M.A.T., Designated Federal Officer, OID, CDC, 1600 Clifton Road, NE., Mailstop D10, Atlanta, Georgia 30333, Telephone: (404)639–4461.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: November 4, 2010.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2010–28581 Filed 11–12–10; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of Biotechnology Activities Recombinant DNA Research: Proposed Actions Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)

ACTION: Notice of consideration of proposed actions under the *NIH Guidelines.*

SUMMARY: A request to certify *Kluyveromyces lactis* as a new host-vector system has been submitted to the NIH Office of Biotechnology Activities (OBA). The data to be considered for certifying a new host-vector system can be found in Appendix I of the *NIH Guidelines.* A new host-vector system may be certified only after review by the NIH Recombinant DNA Advisory Committee (RAC) and specifically approved by the NIH Director as a Major Action.

Part of this request is to exempt from the *NIH Guidelines* certain types of research when performed in *K. lactis,* if *K. lactis* and its affiliated plasmids meet the requirements for certification as a host-vector system. Research that is exempt from the *NIH Guidelines* when performed with other certified host-vector systems can be found in Appendix C of the *NIH Guidelines.*

DATES: The public is encouraged to submit written comments on these proposed actions. Comments may be submitted to OBA in paper or electronic form at the OBA mailing, fax, and e-mail addresses shown below under the heading **FOR FURTHER INFORMATION CONTACT**. The NIH will consider all comments submitted by December 1, 2010. Written comments submitted by December 1, 2010 will be reproduced and distributed to the RAC for consideration at its December 7–8, 2010 meeting. In addition, an opportunity for public comment will be provided at that meeting. Please check the meeting agenda for the time of this discussion (*http://oba.od.nih.gov/rdna_rac/rac_meetings.html*). All written comments received in response to this notice will be available for public inspection at the NIH OBA office, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892 (telephone, 301–496–9838), weekdays between the hours of 8:30 a.m. and 5 p.m.

FOR FURTHER INFORMATION CONTACT: OBA by e-mail at *oba@od.nih.gov,* or telephone at 301–496–9838, if you have questions, or require additional information about these proposed actions. Comments may be submitted to the same e-mail address or by fax at 301–496–9839 or sent by U.S. mail to the Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, Maryland 20892–7985. For additional information about the RAC meeting at which these proposed actions will be deliberated, please visit the NIH OBA Web site at: <*http://oba.od.nih.gov/oba/index.html*>.

SUPPLEMENTARY INFORMATION: OBA has received a request from the Institutional Biosafety Committee at New England BioLabs to exempt from the requirements of the *NIH Guidelines* research with certain plasmids when performed in *K. lactis.* In order for a broad class of research to qualify for exemption, it must be determined by the NIH Director that the research does not pose a significant risk to human health or the environment (Section III–F–6). One way to exempt a broad class of research from the requirements of the *NIH Guidelines* is to perform the research in specific certified host-vector systems (as outlined in Appendix C of the *NIH Guidelines*). Currently research with only three certified host-vector systems is exempt from the *NIH Guidelines.* These three certified systems are based upon two bacterial genera: *Escherichia* (*E. coli* K–12) and *Bacillus* (*B. subtilis* or *B. licheniformis*) and one lower eukaryotic genus: *Saccharomyces* (*S. cerevisiae* or *S. uvarum*). In order to certify a new host-vector system, data as outlined in Appendix I–II–B of the *NIH Guidelines* must be submitted for review. Specifically, this application will be considered under Appendix I–II–B–1 (Host-Vector 1 Systems Other than *Escherichia coli* K–12). Data to be considered include: (i) The strain's natural habitat and growth requirements; its physiological properties, particularly those related to its reproduction, survival, and the mechanisms by which it exchanges genetic information; the range of organisms with which this organism normally exchanges genetic information and the type of information that is exchanged; and any relevant information about its pathogenicity or toxicity; (ii) a description of the history of the particular strains and vectors to be used, including data on any mutations which render this organism less able to survive or transmit genetic information; and (iii) a general description of the range of experiments contemplated with emphasis on the